Evaluate Report to Examine Life After the Patent Cliff, Provides Analysis on Pharmaceutical and Biotech Markets and Consensus Forecasts to 2018

Evaluate to Launch World Preview 2013 Edition at Drug Information Association (DIA) Annual Meeting

LONDON and BOSTON, June 13, 2013 /CNW/ - Patent expirations in 2012 have put the industry through an unprecedented decline in worldwide prescription drug sales in 2012. Now that the pharmaceutical industry has faced the biggest patent cliff it has ever seen, Evaluate Ltd. will examine its effects and what the industry can expect through 2018 in its upcoming annual World Preview report. Evaluate will release the report, which is based on EvaluatePharma® data, on Monday, June 24 in conjunction with the DIA 2013 49^th Annual Meeting in Boston, MA.

The EvaluatePharma World Preview 2013 Edition will include:

• Worldwide prescription and generic drug sales through 2018
• Sales at risk due to patent expirations through 2018
• Sales by therapy area through 2018
• Global pharmaceutical R&D spend
• FDA new drug approval analysis
• Top grossing companies and products by market
• M&A and venture funding analysis

For more information on the 2013 Edition of the World Preview report and to receive your complimentary copy of the Executive Summary, please visit the Evaluate booth #630 at DIA. The summary and full report will be available on the Evaluate web site beginning June 24, 2013. Follow @evaluatepharma on Twitter for a reminder.

If you are attending the 2013 DIA Annual Meeting or the EphMRA 2013 conference and would like to meet, please Contact Us.

About Evaluate Ltd.

Established in 1996, Evaluate Ltd. is the leader in high quality life science sector analysis. EvaluatePharma delivers exclusive consensus forecasts and trusted commercial insight into biotech and pharmaceutical performance. EvaluateMedTech sets a new standard in integrated analysis and consensus forecasts of the global medical device and diagnostic industry. EvaluateClinical Trials delivers unique intelligence to efficiently and accurately analyze the global clinical trial landscape. A team of over 85 dedicated healthcare analysts employ rigorous methodologies to collate, organize and deliver the most-up-to-date commercial performance data available. An award winning editorial team of journalists writing under the EP Vantage name support EvaluatePharma's analysis. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit http://www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.

SOURCE: Evaluate Ltd.

Media Contacts:
Evaluate and EP Vantage
Christine Lindgren
[phone]
[email protected]

Chempetitive Group (for US media)
Rachel Lear
Kelly Quigley
[phone]
[email protected]

College Hill (for non-US media)
Melanie Toyne Sewell / Stephanie Bacher / Gemma Howe
[phone]
[email protected]